What is Zymeworks's estimated fair value?

Zymeworks (ZYME) reported estimated fair value of $159.56M in Q1 2026.

How has Zymeworks's estimated fair value changed year-over-year?

Zymeworks's estimated fair value decreased by 35.0% year-over-year, from $245.41M to $159.56M.

What is the long-term trend for Zymeworks's estimated fair value?

Over 2 years (2023 to 2025), Zymeworks's estimated fair value has grown at a -12.4% compound annual growth rate (CAGR), from $298.7M to $229.43M.

Zymeworks ZYME Estimated Fair Value

Estimated Fair Value at other companies

Summit TherapeuticsSMMT

——

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's estimated fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's estimated fair value?: Zymeworks (ZYME) reported estimated fair value of $159.56M in Q1 2026.
How has Zymeworks's estimated fair value changed year-over-year?: Zymeworks's estimated fair value decreased by 35.0% year-over-year, from $245.41M to $159.56M.
What is the long-term trend for Zymeworks's estimated fair value?: Over 2 years (2023 to 2025), Zymeworks's estimated fair value has grown at a -12.4% compound annual growth rate (CAGR), from $298.7M to $229.43M.